By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

ImmunoGen, Inc. 

128 Sidney Street

Cambridge  Massachusetts  02139-4239  U.S.A.
Phone: 617-995-2500 Fax: 617-995-2510


SEARCH JOBS




Collaborations

GlaxoSmithKline (North Carolina) 

Raven Biotechnologies, Inc.  Partnership for the discovery and development of therapeutic MAbs for the treatment of ovarian cancer.

Medarex, Inc.  Partnership for the discovery and development of therapeutic MAbs for the treatment of ovarian cancer.





Company News
Why ImmunoGen (IMGN) Investors are Waiting on Bated Breath to Move "FORWARD" 2/22/2017 5:42:04 AM
ImmunoGen (IMGN) Reports Recent Progress And Operating Results For Six-Month Period And Quarter Ended December 31, 2016 2/17/2017 6:30:06 AM
ImmunoGen (IMGN) Announces First Patient Dosed In FORWARD I Phase 3 Study Of Mirvetuximab Soravtansine In Platinum-Resistant Ovarian Cancer 1/27/2017 10:11:39 AM
ImmunoGen (IMGN) Announces Conference Call To Discuss Its Results For Six-Month Period And Quarter Ended December 31 1/26/2017 10:20:36 AM
ImmunoGen (IMGN) Release: Biotech Announces Departure Of Sandra Poole 1/24/2017 8:57:24 AM
ImmunoGen (IMGN) CEO Sees Potential in Company‚Äôs Lead ADC Product 1/18/2017 6:50:25 AM
ImmunoGen (IMGN) Announces Mirvetuximab Soravtansine Phase 1 Expansion Cohort Results In Platinum-Resistant Ovarian Cancer Published In The Journal Of Clinical Oncology 12/28/2016 9:03:02 AM
ImmunoGen (IMGN) Release: Preclinical Data On IMGN632, A Novel CD123-Targeting ADC, Presented At American Society of Hematology Annual Meeting 12/6/2016 11:37:21 AM
ImmunoGen (IMGN) To Present Preclinical Data Highlighting Potential Of Combining Mirvetuximab Soravtansine With An Immune Checkpoint Inhibitor At SITC 2016 Annual Meeting 11/11/2016 11:45:56 AM
ImmunoGen (IMGN) Reports Financial Results For Quarter Ended September 30 And Reviews Business Highlights 10/28/2016 12:26:47 PM
12345678910...
//-->